Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Common Equity (2016 - 2017)

Historic Common Equity for Tenax Therapeutics (TENX) over the last 7 years, with Q3 2017 value amounting to $10.2 million.

  • Tenax Therapeutics' Common Equity fell 7823.15% to $10.2 million in Q3 2017 from the same period last year, while for Sep 2017 it was $10.2 million, marking a year-over-year decrease of 7823.15%. This contributed to the annual value of $17.1 million for FY2016, which is N/A changed from last year.
  • Tenax Therapeutics' Common Equity amounted to $10.2 million in Q3 2017, which was down 7823.15% from $11.3 million recorded in Q2 2017.
  • In the past 5 years, Tenax Therapeutics' Common Equity ranged from a high of $82.9 million in Q2 2014 and a low of -$1.8 million during Q2 2013
  • Moreover, its 5-year median value for Common Equity was $17.1 million (2016), whereas its average is $32.8 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 41381.49% in 2013, then skyrocketed by 475993.72% in 2014.
  • Tenax Therapeutics' Common Equity (Quarter) stood at -$1.8 million in 2013, then surged by 4759.94% to $82.9 million in 2014, then dropped by 27.07% to $60.4 million in 2015, then crashed by 71.63% to $17.1 million in 2016, then tumbled by 40.7% to $10.2 million in 2017.
  • Its Common Equity was $10.2 million in Q3 2017, compared to $11.3 million in Q2 2017 and $14.1 million in Q1 2017.